Search
Odyssey Therapeutics Ord Shs (Proposed)
ODTXAdd to Watchlist
19.930USD
-0.830-4.00%
Close 09-23 16:00（ET）
957.24MMarket Cap
LossP/E TTM
Odyssey Therapeutics Ord Shs (Proposed) (ODTX) Stock Price Target & Forecast
Analyst Rating
Based on 5 analysts giving stock ratings to Odyssey Therapeutics Ord Shs (Proposed) in the past month.
Buy
2 Strong Buy
3 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
38.000USD+83.04%
ODTX Analyst Recommendation Trends
In the current month, ODTX has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ODTX average Analyst price target in the last month is 38.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
2
2
0
0
0
0
0
0
3
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
5
0
0
0
0
0
0
ODTX Analyst Rating for Peer Comparison
Updated: Sep 24, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, ODTX EPS is projected to reach -1.103 in FY2026Q3, following reported EPS of -1.744 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
--
-1.25
-1.01
-1.10
-1.14
Actual
-3.15
-0.81
-1.74
--
--
Surprise
--
+35.24%
-72.28%
--
--
FAQs
What is Odyssey Therapeutics Ord Shs (Proposed)'s price target?
Analysts forecast that Odyssey Therapeutics Ord Shs (Proposed)'s price target is USD 38.00, with the highest forecast at USD 44.00 and the lowest forecast at USD 30.00.
How have Odyssey Therapeutics Ord Shs (Proposed)ODTX's recent earnings per share performed?
The market expectation was USD -1.74, while Odyssey Therapeutics Ord Shs (Proposed)ODTX's earnings per share (EPS) for the previous quarter was USD -0.81. EPS for the next quarter is expected at USD -1.14.
What is the analyst rating for Odyssey Therapeutics Ord Shs (Proposed)?
Based on the ratings of Odyssey Therapeutics Ord Shs (Proposed)'s stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.